Hemopericardium in a Sirolimus-Treated Renal Transplant Patient

Sirolimus is an immunosuppressant frequently prescribed to prevent graft-vs-host disease in renal transplant patients. Pericardial effusion is recognized as a rare and potentially lethal side effect of this medication. Hemopericardium, specifically, is an even rarer complication that has yet to be r...

Descripción completa

Detalles Bibliográficos
Autores principales: Groudan, Kevin, Sawalha, Khalid, Bhat, Anusha G, Eltanbedawi, Ahmed, Ambesh, Paurush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458718/
https://www.ncbi.nlm.nih.gov/pubmed/32879829
http://dx.doi.org/10.7759/cureus.9508
Descripción
Sumario:Sirolimus is an immunosuppressant frequently prescribed to prevent graft-vs-host disease in renal transplant patients. Pericardial effusion is recognized as a rare and potentially lethal side effect of this medication. Hemopericardium, specifically, is an even rarer complication that has yet to be reported in the literature. We report the first case of sirolimus-induced hemopericardium in a renal transplant patient.

Ejemplares similares